248 related articles for article (PubMed ID: 19888874)
21. Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer.
Raez LE; Kobina S; Santos ES
Clin Lung Cancer; 2010 Jan; 11(1):18-24. PubMed ID: 20085863
[TBL] [Abstract][Full Text] [Related]
22. Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer.
Smith JW; McIntyre KJ; Acevedo PV; Encarnacion CA; Tedesco KL; Wang Y; Asmar L; O'Shaughnessy JA
Breast Cancer Res Treat; 2009 Nov; 118(2):361-7. PubMed ID: 19459042
[TBL] [Abstract][Full Text] [Related]
23. A better platinum-based anticancer drug yet to come?
Olszewski U; Hamilton G
Anticancer Agents Med Chem; 2010 May; 10(4):293-301. PubMed ID: 20187870
[TBL] [Abstract][Full Text] [Related]
24. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?
Oh WK; Tay MH; Huang J
Cancer; 2007 Feb; 109(3):477-86. PubMed ID: 17186531
[TBL] [Abstract][Full Text] [Related]
25. Oxaliplatin: a review of preclinical and clinical studies.
Raymond E; Chaney SG; Taamma A; Cvitkovic E
Ann Oncol; 1998 Oct; 9(10):1053-71. PubMed ID: 9834817
[TBL] [Abstract][Full Text] [Related]
26. Satraplatin for hormone-refractory prostate cancer.
Kerr C
Lancet Oncol; 2007 Apr; 8(4):290. PubMed ID: 17431954
[No Abstract] [Full Text] [Related]
27. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
28. Platinum anticancer drugs. From serendipity to rational design.
Monneret C
Ann Pharm Fr; 2011 Nov; 69(6):286-95. PubMed ID: 22115131
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors.
Galsky MD; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Ann Oncol; 2012 Apr; 23(4):1037-44. PubMed ID: 21828377
[TBL] [Abstract][Full Text] [Related]
30. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.
Stordal B; Pavlakis N; Davey R
Cancer Treat Rev; 2007 Jun; 33(4):347-57. PubMed ID: 17383100
[TBL] [Abstract][Full Text] [Related]
31. Satraplatin in the treatment of hormone-refractory metastatic prostate cancer.
Armstrong AJ; George DJ
Ther Clin Risk Manag; 2007 Oct; 3(5):877-83. PubMed ID: 18473011
[TBL] [Abstract][Full Text] [Related]
32. New-generation platinum agents for solid tumors.
Shah N; Dizon DS
Future Oncol; 2009 Feb; 5(1):33-42. PubMed ID: 19243296
[TBL] [Abstract][Full Text] [Related]
33. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
34. Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance.
Kalimutho M; Minutolo A; Grelli S; Formosa A; Sancesario G; Valentini A; Federici G; Bernardini S
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1299-312. PubMed ID: 20734047
[TBL] [Abstract][Full Text] [Related]
35. New-generation platinum drugs in the treatment of cisplatin-resistant cancers.
McKeage MJ
Expert Opin Investig Drugs; 2005 Aug; 14(8):1033-46. PubMed ID: 16050795
[TBL] [Abstract][Full Text] [Related]
36. New platinum antitumor complexes.
Kelland LR
Crit Rev Oncol Hematol; 1993 Dec; 15(3):191-219. PubMed ID: 8142057
[TBL] [Abstract][Full Text] [Related]
37. The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.
Marcus L; Murphy R; Fox E; McCully C; Cruz R; Warren KE; Meyer T; McNiff E; Balis FM; Widemann BC
Cancer Chemother Pharmacol; 2012 Jan; 69(1):247-52. PubMed ID: 21706317
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
39. The emerging role of oxaliplatin in the treatment of gastric cancer.
Zaniboni A; Meriggi F
J Chemother; 2005 Dec; 17(6):656-62. PubMed ID: 16433197
[TBL] [Abstract][Full Text] [Related]
40. [Oxaliplatin: a first DACH-platinum in oncology].
Laadem A; Cvitkovic E
Bull Cancer; 2001 Aug; 88 Spec No():S9-13. PubMed ID: 11567908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]